RevBio has received approval from the U.S. Food and Drug Administration to begin a pilot clinical study of TETRANITE, a regenerative bone adhesive intended to support the repair of complex wrist fractures.
The trial will enrol 20 patients and will assess the safety and effectiveness of the material in injuries involving multiple bone fragments, including fractures that extend into the joint surface.
TETRANITE is designed to fill gaps in bone and support fractured segments while encouraging faster bone growth.
In surgery, it can be used alongside metal plates and screws to improve stability and share load between the implant and the bone.
The material has shown strong bonding capability in laboratory testing and has been studied for its bone-regenerating properties, including research onboard the International Space Station.
The company aims to help reduce post-surgery complications such as nonunion, malunion and hardware failure, which remain common in older patients after wrist and other extremity fractures.
Current treatment approaches, including fixation with pins or plates, can still lead to problems such as nerve issues, tendon injury and infection, contributing to reduced independence and quality of life.
If successful, the technology could provide surgeons with a new option to support quicker and more reliable healing in complex orthopaedic cases.
